SHL Medical and MoonLake will jointly develop the Molly autoinjector for sonelokimab. Credit: SHL Medical / PRNewswire.

MoonLake Immunotherapeutics (MoonLake) has formed a collaboration with SHL Medical to jointly develop an autoinjector for the clinical and commercial supply of its nanobody sonelokimab.

The partnership will leverage SHL Medical’s Molly modular platform technology to develop the autoinjector.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the terms of the collaboration agreement, SHL Medical will provide its expertise in device development, assembly and production to support the drug-device project.

A total of 17 combination products using the proven Molly autoinjector technology have been approved in at least 69 countries.

The technology facilitates home treatment for patients in various therapeutic areas that require injectable drugs.

Sonelokimab is an investigational 40 kDa humanised nanobody that can efficiently neutralise both IL-17F and IL-17A for the treatment of inflammatory disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is currently in clinical development for a number of indications including treating inflammation in patients with hidradenitis suppurativa, a severely debilitating chronic skin condition that leads to irreversible tissue destruction.

The company also presented clinical data at the American Academy of Dermatology Annual meeting to back the hypothesis.

Sonelokimab is smaller in size compared to traditional antibodies and albumin-binding domain, which may enable more efficacy.

SHL Medical CEO Ulrich Faessler said: “Working with MoonLake while sonelokimab is in development allows us to carry out strategies that best complement MoonLake’s clinical and commercial needs.

“We are excited about the collaboration and look forward to potentially bringing the innovative nanobody technology for dermatologic and rheumatic inflammatory indications to patients worldwide.”

MoonLake has already completed the assessment of Sonelokimab in the Phase 2b trial (NCT03384745).

In the randomised, placebo-controlled trial involving 313 patients suffering from moderate-to-severe plaque-type psoriasis, the drug demonstrated a rapid and durable skin-clearance response.

The company expects to reveal top-line results for the MIRA Phase 2 trial of sonelokimab in individuals with moderate-to-severe hidradenitis suppurativa by the end of June this year.

MoonLake Immunotherapeutics chief technical officer Oliver Daltrop said: “As we actively plan for a Phase 3 programme and commercial readiness, SHL’s expertise will greatly enhance our ability to introduce sonelokimab in an autoinjector format that could provide a benefit for patients if approved.”